FHLC News and Press, Fidelity MSCI Health Care Index From 04/07/23

2023-04-07 13:46:45 ET Summary Vanguard's cost-efficient (0.10% expense fee) Health Care ETF is an excellent defensively-oriented fund to hold during challenging economic times. That being the case, the VHT ETF significantly outperformed last week when soft economic data and risin...

2023-03-29 16:33:39 ET Summary Healthcare is considered a defensive sector that should outperform during times of high inflation, weak economic growth, and challenging markets. In addition, demographics should be a tailwind as the U.S. population is aging, and going forward, that ...

2023-03-24 03:00:00 ET Summary We remain selective in taking risk as macro factors continue to drive sentiment. Despite the uncertainties, investors should not lose sight of equities’ enduring role in a well-balanced portfolio. We advocate a near-term focus on resilienc...

2023-03-22 08:54:00 ET Summary Technology and healthcare are good examples of sectors that can play different equity-allocation roles than you might expect. Unlike income-oriented defensive sectors, which are sensitive to changes in interest rates, some of the highest-quality low-...

2023-03-16 15:51:00 ET Summary How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B. What it means for the sector. Why healthcare startups could face funding challenges. The collapse of Silicon Valley Bank is raising concerns about fun...

2023-03-11 04:42:25 ET Summary Fed's aggressive rate hikes, plus SVB crisis, are a big worry right now. Behind the scenes, a (related) biotech stock crisis is also brewing. Market internals remain weak and demand caution going forward. What do a major U.S. commercial...

2023-03-09 02:50:00 ET Summary Rates of change matter, especially for tech companies, and we would expect investors to react favorably to accelerating growth. In healthcare, we continue to find investment opportunities in a difficult macro environment. If the U.S. enters a tra...

2023-03-09 02:20:00 ET Summary Increasing selling pressure among biotech stocks is a major concern. While the market's intermediate-term path is still up, the short-term outlook is weakening. Beware higher volatility in March as healthcare sector selling pressure persists. ...

Summary We think healthcare companies are quite resilient during periods of inflation because their products are not substitutable and they deliver innovation. Healthcare has lagged behind many other areas in terms of its adoption of technology. We think, regardless of the market en...

Summary We think value stocks can outperform as interest rates head higher. Regions and sectors help us find quality within value and growth at a reasonable price. Stocks slid after the Federal Reserve’s preferred inflation gauge showed persistently high inflation, reinforcing wh...